Global Chronic Idiopathic Constipation (CIC) Drugs Market By Drug Type (Lubiprostone, Linaclotide, Pipeline Drug Analysis: Phase 3: Plecanatide, Elobixibat, Others), Prescription Type (Prescribed, Over the Counter Drugs) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2022

The global chronic idiopathic constipation (CIC) drugs market is moderately competitive and is characterized by a large demand for over the counter medications. Considering CIC as a symptom and not a disorder, there is a greater tendency of patients towards opting for self-medication through OTC drugs. This report on CIC drugs market studies, estimates and forecasts the market for various drugs indicated for the treatment of chronic idiopathic constipation. The global CIC drugs market report studies this market for drug types, prescription type and geographical distribution.

In terms of drug type, the global CIC market is studied for Lubiprostone, Linaclotide and other drugs. The market size and forecast for these segments is provided for the period 2014-2022, with respective CAGRs for the period 2016-2022, while considering 2015 as the base year. In addition, this report also studies the market prospects for Plecanatide and Elobixibat, the phase 3 CIC drugs.

The prescription based market for CIC drugs is classified as prescribed CIC drugs market and OTC CIC drugs markets. The prescribed drugs market is further categorized into branded prescribed and generic prescribed CIC drugs segments. The market size and forecast is provided for these segments for the period 2014-2022, with respective CAGRs for 2016-2022.

In terms of geographic distribution, North America, Europe, Asia Pacific and rest of the world regions cumulatively make the global CIC drugs market. These regional markets are further studied for key countries that determine the overall market trends in the regions. The countries considered and studies under each regional break-up include:

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • Rest of the Asia Pacific
  • Rest of the World
    • Latin America
    • Middle East and North Africa
    • Rest

This report includes qualitative market analysis tools such as attractive investment proposition, market dynamics, competition mapping and others. The report concludes with mapping of the key CIC drugs manufacturers operating in the global CIC drugs market.

Chronic Idiopathic Constipation (CIC) drugs are widely adopted across the world, particularly in the regions where the prevalence of the condition is higher. Lubiprostone, Linaclotide, and other laxatives are the major drugs used for CIC treatment.

Chronic Idiopathic Constipation (CIC) Market

At present, the global CIC drugs market is dominated by Lubiprostone drugs with more than 40% market share in 2014. However, due to its proven efficiency, established safety profile and anticipated worldwide commercialization, Linaclotide drugs segment is expected to register the highest growth rate at above 7% during 2016 – 2022. Lubiprostone drugs segment will undergo sharp decline due to its limited efficacy, patent loss and sharp competition against Linaclotide drugs.

Other drugs used for the treatment of chronic constipation disease include Bisacodyl, Chronulac, Constulose, Duphalac, Enulose, (lactulose) Miralax, Glycolax (polyethylene glycol). The medication is available in variety of brand names which enables to draw water into the bowel to soften and loosen the stool. However, the medication may cause side effects such as gas, diarrhea, upset stomach, and stomach cramps.

For the purpose of this study, the global Chronic Idiopathic Constipation (CIC) Drugs market is categorized into:

  • North America (US and Canada)
  • Europe (UK, Germany and Rest of Europe)
  • Asia Pacific (China, Japan and Rest of Asia Pacific)
  • Rest of the World (Middle East and Africa, and Latin America)

Chronic Idiopathic Constipation (CIC) Market

North America leads the global CIC drugs market and was valued at USD 767.7 Mn in 2015. Functional disorders such as IBS and CIC affect a large section of the North American population. Large geriatric population pool and higher reference to professional assistance for treating disorders will contribute to the growth in demand for prescribed CIC drugs in North America. Additional studies have also reported that patient distribution of CIC varies across North America and intensifies in rural and distant regions. Hence, further demand for efficient CIC drugs in these regions is anticipated in North America market. US is the largest CIC drugs market in North America and worldwide.

The CIC drugs market has been steadily growing in Europe. National governments in the region are perpetually evolving and are striving towards toning down the administration cost and attending time. This has created a need for novel, cost effective and safer drugs for treating CIC.

The drug market has steady growth in this region as the government is continuously involved in taking initiatives and steps to treat and to improve the healthcare segment of the society by providing latest technological and advance medication treatments support. 

Based on prescription type, the global chronic idiopathic constipation (CIC) drugs market is segmented into prescription and OTC drugs market. Furthermore, the prescribed CIC drugs market is further studied for generic and branded OIC drugs.

Chronic Idiopathic Constipation (CIC) Market

Constipation is never considered as a disease but a syndrome or a side effect, people are less likely to visit doctors to get prescription for constipation. Thus, the CIC drugs market is dominated by over the counter prescription with over 50% market share in 2014. The OTC drugs market will continue to dominate the market growing at the highest CAGR during 2016-2022.

Over-the-counter fiber products such as psyllium (brand name Metamucil), polycarbophill (FiberCon) and methylcellulose (Citrucel) are usually the best first choice for constipation. Higher preference for OTC drugs is a big trend in developing markets of Asia Pacific and rest of the world. It is expected that the same trend will continue during the forecast period in the mentioned regional markets.


Chronic Idiopathic Constipation (CIC) is characterized by chronic presence of constipation symptoms due to unknown causes and not due to any underlying illness or an effect of medication. 16% to 17% adults in Europe and US suffer with constipation. Chronic constipation is more common among women and older adults over the age of 65. Among these, 80% of the institutionalized geriatrics are reported to suffer from chronic constipation.

Chronic Idiopathic Constipation (CIC) Market

The global chronic idiopathic constipation drugs market is expected to undergo significant growth in the next few years due to the phenomenal growth in disease prevalence and geriatric population pool, which has led to growing adoption of CIC drugs. FDA approvals and ongoing successful clinical trials are driving this market towards growth. Moreover, growing geriatric population and rise in healthcare spending across both developed and developing regions are creating potential scope for global CIC drugs market.

North America has the highest contribution in the CIC drugs market by over the counter (OTC) drugs. There is a huge demand for prescribed constipation drugs in developed markets of US, US, Germany, France, Spain and others. Bisacodyl, Senna and polyethylene glycol are some of the major OTC drugs widely adopted across the world.

Future regulatory approvals for Elobixibat and Plecanatide are expected to create further growth opportunities in the market. For instance, Lecanatide has successfully accomplished phase 3 trials for CIC treatment and is being under further evaluation for IBS-C. It is observed that CIC market is open for further novel pharmacological solutions, thus exhibits additional growth potential for market entrants.

CIC drugs assist in alleviating abdominal pain, straining and facilitates bowel movements in patients. Lubiprostone efficiently provides relief from these conditions and is also used for treating IBS-C. On the other hand, sertain patient specific side effects such as nausea, occasional stomach pain, tightness of throat and others may hold back the demand for newer drugs. Thus the market players are increasingly focusing on introduction of further safer pharmacological alternatives.

Growth in awareness about the disease and increase in disease prevalence, particularly the geriatric patient pool has urged the need for prompt and safest possible CIC drugs. The CIC drugs market is estimated to reach USD 2.5 Bn by 2022, progressing at a CAGR of 6.4% during 2016-2022. Growth in demand for CIC drugs in developing markets of Asia Pacific and rest of the world serve as a significant opportunity for the market players intending to enhance their international footprint. The huge gap of unmet needs in the lesser developed economies coupled with growing healthcare awareness will serve as growth facilitators in these regions.

Choose License Type
Published Date:  Mar 2016
Category:  Pharmaceuticals
Report ID:   57738
Report Format:   PDF
Pages:   120
Rating:    4.2 (51)
Connect With Us
24/7 Research Support